disease

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced on Wednesday a collaboration with AbCellera Biologics Inc. (NASDAQ:ABCL) to discover next-generation T-cell-engaging multispecific antibodies. • Jazz Pharmaceuticals stock is showing positive momentum. What’s ahead for JAZZ stock?...

Jazz Pharmaceuticals PLC's (NASDAQ:JAZZ) revenue growth and stock valuation is being driven by the adoption of Ziihera as a first-line (1L) treatment of HER2-positive (HER2+) metastatic gastroesophageal adenocarcinoma (GEA), according to BofA Securities. • Jazz Pharmaceuticals stock is...

Incyte Corporation (NASDAQ:INCY) said Monday it has agreed to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, in a deal valued at $1.25 billion upfront. The transaction will add late-stage candidate VGA039 to Incyte's hematology portfolio and could reach a total value of...

WW International (NASDAQ:WW) on Thursday said its Weight Watchers platform is now available through Eli Lilly Co.'s (NYSE:LLY) LillyDirect digital health care platform, expanding access to branded GLP-1 weight-loss medications alongside clinical and behavioral support services. • Eli Lilly...

AstraZeneca Plc (NASDAQ:AZN) on Tuesday reported updated Phase 3 SERENA-6 trial results showing that camizestrant combined with a CDK4/6 inhibitor continued to deliver significant progression-free survival benefits in hormone receptor-positive, HER2-negative advanced breast cancer. • ...

Rezolute, Inc. (NASDAQ:RZLT) reported an interim update from its ongoing Phase 3 upLIFT study evaluating ersodetug in patients with tumor hyperinsulinism (HI), saying six of the eight participants enrolled so far achieved the study's primary endpoint. Tumor hyperinsulinism is a rare condition...

AstraZeneca Plc (NASDAQ:AZN) on Monday reported Phase 3 EMERALD-3 trial results showing that its immunotherapy-based STRIDE regimen, when combined with lenvatinib and transarterial chemoembolization (TACE), significantly improved progression-free survival in patients with unresectable...

Moderna, Inc. (NASDAQ:MRNA) stock is trading lower on Monday. The COVID-19 vaccine maker and Merck & Co Inc. (NYSE:MRK) reported five-year follow-up results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of individualized neoantigen therapy intismeran autogene (mRNA-4157/V940) plus KEYTRUDA...

GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotech company, is trading higher on Wednesday as investors assess the company's recent financing deal alongside growing attention on its vaccine platform developments. • Geovax Labs stock is charging ahead with explosive momentum. Why are...

U.S. cancer centers are moving quickly to enroll patients in an expanded access program for a pancreatic cancer drug developed by Revolution Medicines Inc. (NASDAQ:RVMD) after clinical trial results showed the treatment significantly extended survival in patients with advanced disease. • ...

Protara Therapeutics Inc. (NASDAQ:TARA) reported updated 12-month Phase 2 data for TARA-002 in patients with Bacillus Calmette-Guérin (BCG)-naïve non-muscle invasive bladder cancer (NMIBC), highlighting durable complete response rates and a favorable safety profile. The updated findings from Cohort...

REGENXBIO Inc. (NASDAQ:RGNX) on Thursday released topline and interim functional data from the pivotal Phase 1/2/3 AFFINITY DUCHENNE trial evaluating RGX-202, its investigational gene therapy for Duchenne muscular dystrophy. The company said the study met its primary endpoint with high statistical...

Moleculin Biotech Inc. (NASDAQ:MBRX) said it remains on track to unblind the first set of data from its pivotal Phase 2B/3 MIRACLE trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML), before June 30, 2026. • Moleculin Biotech...

Earlier this year, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) initiated discussions with the FDA for the design of a registrational study for its experimental drug REC-4881 in familial adenomatous polyposis (FAP), which represents a new way of treating this rare genetic condition without immediate...

Oncolytics Biotech, Inc. (NASDAQ:ONCY) shares are up on Monday as the company reported promising durability data for its investigational immunotherapy, pelareorep, in treating metastatic colorectal cancer. • Oncolytics Biotech shares are powering higher. What’s behind ONCY gains?...